All In Biotech

Drug Trial Radar · NCT00908596

Primovist / Eovist in Renally Impaired Patients

Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Primovist/Eovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.

Last checked: Nov 20, 2026Latest source record: Jul 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

357

Actual

Start

May 2009

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
May 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Primovist/Eovist, will be asked to participate. The administration of contrast agents that contain gadolinium such as Primovist/Eovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in patients with renal impairment. This study is to assess the potential risk to develop NSF in patients with renal impairment after the administration of Primovist/Eovist. Patients who are enrolled in this study will receive a Primovist/Eovist enhanced MRI scan which was prescribed by the referring doctor. After the MRI scan the patient will be included in a two year follow-up period to assess if signs or symptoms suggestive of NSF have appeared.

Conditions

  • Contrast Media

Interventions

  • Gadoxetic acid disodium (Primovist, BAY86-4873)Drug

    Primovist/Eovist in approved indications at approved dosages

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and Histopathological InformationTime frame: Up to 24 months following the administration of Primovist/Eovist

Locations

47 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Topeka, Kansas

  • Site not named

    Baltimore, Maryland

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Brooklyn, New York

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Memphis, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Westmead NSW, Australia

  • Site not named

    Herston, Queensland, Australia

  • Site not named

    Woollongabba, Queensland, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Geelong, Victoria, Australia

  • Site not named

    Graz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Heidelberg, Baden-Wurttemberg, Germany

  • Site not named

    Stuttgart, Baden-Wurttemberg, Germany

  • Site not named

    Erlangen, Bavaria, Germany

  • Site not named

    Frankfurt am Main, Hesse, Germany

  • Site not named

    Marburg, Hesse, Germany

  • Site not named

    Hanover, Lower Saxony, Germany

  • Site not named

    Dortmund, North Rhine-Westphalia, Germany

  • Site not named

    Essen, North Rhine-Westphalia, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Magdeburg, Saxony-Anhalt, Germany

  • Site not named

    Berlin, State of Berlin, Germany

  • Site not named

    Gera, Thuringia, Germany

  • Site not named

    Brescia, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Naples, Italy

  • Site not named

    Palermo, Italy

  • Site not named

    Pisa, Italy

  • Site not named

    Rozzano, Milano, Italy

  • Site not named

    Pozzuoli, Napoli, Italy

  • Site not named

    Candiolo, Torino, Italy

  • Site not named

    Seoul, South Korea

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.